AstraZeneca Pharma India Limited (IN:ASTRAZEN)
:ASTRAZEN
Want to see IN:ASTRAZEN full AI Analyst Report?
ASTRAZEN Stock Chart & Stats
₹8431.70
₹585.60(8.51%)
At close: 4:00 PM EST
₹8431.70
₹585.60(8.51%)
Day’s Range― - ―
52-Week Range₹7,630.00 - ₹10,653.05
Previous CloseN/A
Volume65.42K
Average Volume (3M)602.00
Market Cap
₹215.27B
Enterprise Value₹211.59B
Total Cash (Recent Filing)₹4.10B
Total Debt (Recent Filing)₹347.90M
Price to Earnings (P/E)173.1
Beta0.72
Next Earnings
May 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)79.66
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio-6.48
Price to Book (P/B)27.56
Price to Sales (P/S)12.39
P/FCF Ratio333.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained revenue expansion (more than double from 2022 to 2025) signals durable market demand for its branded specialty and chronic therapies. This scale supports stronger commercial reach, funds marketing and distribution, and underpins long‑term cash generation and reinvestment capacity.
Robust Cash GenerationImproved operating cash conversion and consistently positive free cash flow indicate the business reliably converts earnings into cash. That durability funds capex, working capital and strategic initiatives while reducing refinancing risk and supporting sustainable operations.
Low Financial LeverageVery low leverage and a growing equity base provide financial flexibility to absorb shocks, invest in commercial expansion or fund product rollouts. A strong balance sheet supports long‑term strategic initiatives and lowers probability of liquidity stress.
Bears Say
Declining Net Profit MarginSignificant margin compression halved reported net margin in one year, reducing retained earnings and free cash available for reinvestment or shareholder returns. If higher operating costs or pricing pressures persist, profitability and long‑term cashflow resilience could be impaired.
Falling Return On EquityA steady ROE decline despite equity growth indicates diminishing efficiency of capital deployment. Over time this can lower shareholder returns and signal that incremental investments generate weaker profits, pressuring strategic options and investor expectations.
Dependence On Parent For PortfolioAs a subsidiary, the company’s growth cadence, access to new patented or specialty products, and pricing/transfer arrangements depend on parent decisions. This structural reliance limits autonomous pipeline diversification and ties local revenue risk to global launch timing and strategy.
AstraZeneca Pharma India Limited News
ASTRAZEN FAQ
What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹7630.00 and its highest was ₹10653.05 in the past 12 months.
What is AstraZeneca Pharma India Limited’s market cap?
AstraZeneca Pharma India Limited’s market cap is ₹215.27B.
When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
AstraZeneca Pharma India Limited’s upcoming earnings report date is May 30, 2026 which is in 9 days.
How were AstraZeneca Pharma India Limited’s earnings last quarter?
AstraZeneca Pharma India Limited released its earnings results on Feb 11, 2026. The company reported ₹13.036 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.036.
Is AstraZeneca Pharma India Limited overvalued?
According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Overvalued.
Does AstraZeneca Pharma India Limited pay dividends?
AstraZeneca Pharma India Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.35%. See more information on AstraZeneca Pharma India Limited dividends here
What is AstraZeneca Pharma India Limited’s EPS estimate?
AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AstraZeneca Pharma India Limited have?
AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
AstraZeneca Pharma India Limited reported an EPS of ₹13.036 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
Currently, no hedge funds are holding shares in IN:ASTRAZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Technical Analysis
Alkem Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―